Eliana Merle
Stock Analyst at Barclays
(3.69)
# 753
Out of 5,143 analysts
108
Total ratings
45.57%
Success rate
9.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Downgrades: Underweight | $9 → $0.3 | $0.42 | -29.13% | 5 | Feb 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $606 → $607 | $481.01 | +26.19% | 2 | Feb 17, 2026 | |
| QURE uniQure | Initiates: Equal-Weight | $31 | $24.47 | +26.71% | 5 | Jan 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $59 | $33.30 | +77.18% | 2 | Jan 28, 2026 | |
| TPG TPG Inc. | Initiates: Overweight | $78 | $42.34 | +84.22% | 1 | Jan 28, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Equal-Weight | $8 | $5.28 | +51.52% | 2 | Jan 28, 2026 | |
| PTCT PTC Therapeutics | Upgrades: Overweight | $68 → $119 | $70.50 | +68.79% | 1 | Jan 28, 2026 | |
| MBX MBX Biosciences | Initiates: Overweight | $66 | $36.75 | +79.59% | 1 | Jan 28, 2026 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Overweight | $964 | $437.79 | +120.20% | 6 | Jan 28, 2026 | |
| IVA Inventiva | Initiates: Overweight | $18 | $6.71 | +168.26% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $231 | $159.03 | +45.26% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $234.95 | +45.56% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.68 | +240.91% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $67.91 | +17.80% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $24 | $22.47 | +6.81% | 9 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $329.35 | +60.01% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $40 → $34 | $50.29 | -32.39% | 9 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $4.52 | +430.97% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $57.93 | -84.46% | 4 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $54.29 | -63.16% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $113 → $114 | $62.92 | +81.18% | 3 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $18.12 | -33.77% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.16 | +270.37% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $12.30 | +70.73% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $88.43 | -20.84% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $2.45 | -10.20% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $103.69 | -31.53% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $109.93 | +19.17% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $26.68 | -81.26% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $40.86 | -55.95% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $19.51 | +12.76% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $7.94 | +491.94% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.36 | +11.42% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $33.87 | +295.63% | 3 | Aug 19, 2020 |
Gossamer Bio
Feb 24, 2026
Downgrades: Underweight
Price Target: $9 → $0.3
Current: $0.42
Upside: -29.13%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Overweight
Price Target: $606 → $607
Current: $481.01
Upside: +26.19%
uniQure
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $31
Current: $24.47
Upside: +26.71%
Tyra Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $33.30
Upside: +77.18%
TPG Inc.
Jan 28, 2026
Initiates: Overweight
Price Target: $78
Current: $42.34
Upside: +84.22%
Sagimet Biosciences
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $5.28
Upside: +51.52%
PTC Therapeutics
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $70.50
Upside: +68.79%
MBX Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $36.75
Upside: +79.59%
Madrigal Pharmaceuticals
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $437.79
Upside: +120.20%
Inventiva
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $6.71
Upside: +168.26%
Jan 28, 2026
Initiates: Overweight
Price Target: $231
Current: $159.03
Upside: +45.26%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $234.95
Upside: +45.56%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $9.68
Upside: +240.91%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $67.91
Upside: +17.80%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $24
Current: $22.47
Upside: +6.81%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $329.35
Upside: +60.01%
Jan 7, 2026
Assumes: Neutral
Price Target: $40 → $34
Current: $50.29
Upside: -32.39%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $4.52
Upside: +430.97%
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $57.93
Upside: -84.46%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $54.29
Upside: -63.16%
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $62.92
Upside: +81.18%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $18.12
Upside: -33.77%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.16
Upside: +270.37%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $12.30
Upside: +70.73%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $88.43
Upside: -20.84%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $2.45
Upside: -10.20%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $103.69
Upside: -31.53%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $109.93
Upside: +19.17%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $26.68
Upside: -81.26%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $40.86
Upside: -55.95%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $19.51
Upside: +12.76%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $7.94
Upside: +491.94%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.36
Upside: +11.42%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $33.87
Upside: +295.63%